Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of TP-3654 Formulations in Healthy Volunteers
NCT06389955Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- May 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nuvisertib in myelofibrosis (MF) (7 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Maximum Concentration of TP-3654 (Capsule) at 2 weeks, Area Under the Curve of TP-3654 (Capsule) at 2 weeks and 2 more. Started May 2023; status: completed.
02
Drugs
nuvisertib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06389955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389955.